NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF ONCOMATRYX BIOPHARMA, S.A.

In Derio (Bizkaia), July 28, 2026

Dear Shareholder:

You are hereby invited to attend the extraordinary general meeting of Oncomatryx Biopharma, S.A. (the "Company"), to be held on September 16, 2026, at 12:00 p.m., at the Company's registered office, located in Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (zip code 48160), without prejudice to allowing both in-person attendance at the registered office and attendance via teleconference in accordance with the provisions of the Capital Companies Act and Article 15 of the Company's Articles of Incorporation, with the following:

AGENDA

First. - Reduction of the Company's share capital through the redemption of four hundred sixty-eight thousand five hundred fifty-two (468,552) treasury shares.

Second. - Appointment, for the term specified in the bylaws, of Fundación Bancaria Kutxa–Kutxa Banku Fundazioa as a member of the Company's board of directors.

Third. - Setting the maximum number of directors, within the minimum and maximum limits established in the articles of incorporation.

Fourth. - Amendment of Article 25 of the Company's articles of incorporation, effective January 1, 2027. Replacement of the CEO's variable compensation.

Fifth. - Approval of the maximum compensation for the CEO, effective January 1, 2027.

Sixth. - Determination of the CEO's compensation, effective January 1, 2027.

Seventh. **-** Delegation of powers.

Eighth. **-** Drafting, reading, and, if applicable, approval of the minutes of the meeting.

Right to Information. Shareholders have the right to examine the following documents at the company's registered office, located at Parque Tecnológico de Vizcaya, 801-B-2º, Derio (Bizkaia) (zip code 48160), or to request that a copy be provided or sent to them free of charge (which may be sent via email with a return receipt if the shareholder agrees to this method):

1. The full text of the proposed resolutions corresponding to the agenda items, submitted by the Board of Directors; and

2. The Board of Directors' report on the proposed capital reduction.

3. The Board of Directors' report on the amendment to the bylaws regarding the CEO's compensation.

Similarly, in accordance with the provisions of Article 197 of the Capital Companies Act, up to the seventh day prior to the date scheduled for the general meeting, shareholders may request from the Board of Directors any information or clarifications they deem necessary regarding the matters on the agenda, or submit in writing any questions they consider relevant.

During the general meeting, the Company's shareholders may verbally request any information or clarifications they deem appropriate regarding the items on the agenda.

Right to Add Items to the Agenda. In accordance with the provisions of Article 15 of the Company's Articles of Incorporation and Article 172 of the Capital Companies Act, shareholders holding shares representing at least 5% of the share capital may request the publication of a supplement to the notice of the general shareholders' meeting, including one or more items on the agenda.

This right must be exercised by means of a certified notice, which must be received at the Company's registered office within 5 days following the publication of the notice of the meeting. The supplement to the notice of the meeting must be published at least 15 days prior to the date set for the general shareholders' meeting.

Right to Attend. In accordance with the provisions of Article 19 of the Company's Articles of Incorporation, shareholders whose shares are registered in the register of registered shares at least 5 days prior to the date on which the general meeting is to be held, and shareholders who provide proof through a public document of their lawful acquisition of shares from the person listed as the holder in the register, shall have the right to attend with the right to speak and vote.

Online Attendance. In accordance with the provisions of Article 15 of the Company's Articles of Incorporation, attendance at the General Shareholders' Meeting via videoconference will be permitted. Accordingly, all shareholders will be sent, via individual email to the addresses included in the Company's databases, the *link* to access the meeting. If any shareholder wishes to have the *link* sent to a different email address, they must so indicate and contact the Company at **shareholders@oncomatryx.com**, attaching proof of their shareholder status, at least 5 days prior to the date of the meeting.

Shareholders who wish to attend the General Meeting remotely may participate and cast their vote via the same means, in accordance with the following specifications and instructions:

- The videoconference will be held using the Microsoft Teams platform, which allows all shareholders who wish to do so to attend remotely.

- To access the videoconference, you will need to download the Microsoft Teams application onto your computer, mobile phone, or other electronic devices equipped with a webcam and audio.

- Prior to the videoconference, a web link to join the meeting will be provided via email.

Right of Representation. In accordance with the provisions of Article 19 of the Company's Articles of Incorporation, any shareholder entitled to attend may be represented by another person, even if that person is not a shareholder. The proxy must be granted in writing and specifically for each General Meeting. Any shareholder may exercise their right to be represented by using the proxy form, a template of which will be available on the Company's website (**www.oncomatryx.com**) as of the date of the call for the General Meeting of Shareholders. The proxy must be completed and signed by the shareholder on the corresponding proxy card. The proxy must be accepted by the shareholder's representative; otherwise, it cannot be exercised. To this end, the representative must also sign the proxy card. The representative to whom the proxy is granted must exercise it by attending the General Shareholders' Meeting in person and presenting the proxy card at the place and on the date designated for the General Shareholders' Meeting, starting one hour before the scheduled start time of the meeting. Proxy cards may also be submitted in the days leading up to the meeting at the company's registered office, Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (zip code 48160), or may be sent by the shareholder to the following email address: shareholders@oncomatryx.com.

Voting by Mail. In accordance with the provisions of Article 19 of the Company's Articles of Incorporation, , shareholders may exercise their voting rights by mail, email, or any other means of remote communication. To cast a vote by mail, shareholders must complete and sign the voting card, a template of which will be available on the Company's website (**www.oncomatryx.com**), indicating their vote—in favor, against, abstention, or a blank vote—by placing a check mark in the corresponding box.

The completed and signed ballot must be sent to Oncomatryx Biopharma, S.A. by mail to Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (zip code 48160) or by email to the Chairman at **shareholders@oncomatryx.com**. A shareholder who casts a vote by mail and fails to mark any or all of the boxes intended to indicate a vote on the agenda items shall be deemed to wish to vote in favor of the respective proposals made by the Board of Directors.

A vote cast by mail shall be rendered null and void by a subsequent and express revocation by the shareholder, made through the same means used to cast the vote and within the established deadline for voting, or by the personal attendance at the General Shareholders' Meeting of the shareholder who cast the vote by mail or by the attendance of their representative.

Votes cast by mail must be received by the Company no later than 11:59 p.m. on the day prior to the date scheduled for the General Shareholders' Meeting, that is, no later than 11:59 p.m. on September 15, 2026. Otherwise, the vote shall be deemed not to have been cast. After the aforementioned deadline, only in-person votes cast at the General Shareholders' Meeting by the shareholder in person or by a shareholder validly representing them shall be accepted. A shareholder who casts their vote remotely by mail shall be considered present for the purposes of establishing a quorum for the General Shareholders' Meeting.

Proxy and Voting in the Event of a Supplement to the Notice of Meeting**.** If, as a result of the exercise of the right to include new items on the agenda by shareholders representing at least 5% of the share capital, a supplement to this notice of meeting is published, shareholders who have granted a proxy or cast their vote prior to the publication of said supplement may:

(a) Re-grant proxy with the corresponding voting instructions or cast a new vote with respect to all items on the agenda (including both the original items and the new items added via the supplement); in which case, the previously granted proxy or cast vote shall be deemed revoked and shall be of no effect; or

(b) Provide the corresponding voting instructions to the initially designated representative (who must be the same person; no other representative may be designated) solely with respect to the new agenda items added via the supplement, all in accordance with the procedures and methods mentioned in the preceding sections and using the same method employed in the original delegation or vote cast.

In the event that a shareholder cast a remote vote prior to the publication of the supplement and did not take any of the actions indicated in paragraphs (a) and (b) above, the shareholder shall be deemed to have abstained with respect to those new agenda items.

Derio, July 28, 2026. On behalf of the Board of Directors, the non-director secretary, Mr. Luis Alba Ferré.